| Literature DB >> 27185523 |
Roger Neill Carey1, Chinu Jani2, Curtis Johnson3, Jim Pearce4, Patricia Hui-Ng5, Eduardo Lacson6.
Abstract
Plasma samples collected in tubes containing separator gels have replaced serum samples for most chemistry tests in many hospital and commercial laboratories. Use of plasma samples for blood tests in the dialysis population eliminates delays in sample processing while waiting for clotting to complete, laboratory technical issues associated with fibrin formation, repeat sample collection, and patient care issues caused by delay of results because of incompletely clotted specimens. Additionally, a larger volume of plasma is produced than serum for the same amount of blood collected. Plasma samples are also acceptable for most chemical tests involved in the care of patients with ESRD. This information becomes very important when United States regulatory requirements for ESRD inadvertently limit the type of sample that can be used for government reporting, quality assessment, and value-based payment initiatives. In this narrative, we summarize the renal community experience and how the subsequent resolution of the acceptability of phosphorus levels measured from serum and plasma samples may have significant implications in the country's continued development of a value-based Medicare ESRD Quality Incentive Program.Entities:
Keywords: CMS; Chronic; Hematologic Tests; Humans; Kidney Failure; Medicare; National Quality Forum; Phosphorus; Plasma; Quality Improvement; renal dialysis
Mesh:
Substances:
Year: 2016 PMID: 27185523 PMCID: PMC5012485 DOI: 10.2215/CJN.09310915
Source DB: PubMed Journal: Clin J Am Soc Nephrol ISSN: 1555-9041 Impact factor: 8.237